微粒化地奥司明治疗退行性腰椎滑脱症的疗效观察

目的:观察微粒化地奥司明治疗退行性腰椎滑脱症的疗效。方法:60例退行性腰椎滑脱症患者随机分成两组,每组30例,对照组口服塞来昔布胶囊(200 mg,qd)和甲钴胺片(0.5mg,tid),治疗组在对照组用药基础上口服微粒化地奥司明(1 000mg,bid)。服药期间嘱患者行腰背肌功能锻炼,2周为1个疗程。随访患者至少接受6周治疗,每2周随访1次,连续观察3次。两组均采用改良的中文版Oswestry功能障碍指数(CODI)为观察指标,分别记录治疗后2、4、6周的CODI评分,并评价其临床疗效。结果:两组治疗后CODI与治疗前比较,治疗组治疗2、4、6周后的CODI均低于对照组,差异有统计学意义(P=0.000)。治疗组与对照组的有效率分别为93.3%和70.0%,治疗组的疗效明显好于对照组(P<0.05)。结论:微粒化地奥司明是治疗退行性腰椎滑脱症的一种疗效满意的药物。

Efficacy Observation of Micronized Diosmin for Degenerative Lumbar Spondylolisthesis

OBJECTIVE： To observe therapeutic efficacy of micronized diosmin for degenerative lumbar spondylolisthesis. METHODS： 60 patients with degenerative lumbar spondylolisthesis were randomly divided into 2 groups with 30 cases in each group. Control group was given Celebrex capsule （200 mg, qd） and Mecobalamin tablet （0.5 mg, tid） orally. Treatment group was additionally given micronized diosmin （1 000 mg, bid） on the basis of control group. The patients received low back muscle exercise during treatment, and a treatment course lasted for 2 weeks. The patients received 6 weeks of treatment at least, and followed up every 2 weeks, for 3 times in total. Using modified Oswestry CODI as index, CODI were recorded respectively 2, 4 and 6 weeks after treatment, and clinical efficacy was evaluated. RESULTS： Compared with before treatment, CODI of treatment group were less than those of control group after 2, 4 and 6 weeks of treatment; there was statistical significance （P=0.O00）. The effective rates of treatment group and control group were 93.3% and 70.0%, respectively. Therapeutic efficacy of treatment group was better obviously than that of control group （P〈0.05）. CONCLUSIONS： Micronized diosmin is a kind of satisfactory drugs for degenerative lumbar spondylolisthesis.